Cancerbackup: Medical castration

Skip the page content navigation if you do not require links to content sections within this page.

Page Content Navigation

Skip the main banner if you do not want to read it as the next section.


Page Banner

Want to speak to a specialist cancer nurse? Call free on 0808 800 1234



Skip the main content if you do not want to read it as the next section.


Medical castration (using LNRH analogues and anti-androgens)

LHRH agonists (pituitary down-regulators)

Exposure to LHRH analogues causes the pituitary's LHRH receptors to become desensitised (down-regulated). The down-regulating effect is not immediate but follows an initial stimulation of LH secretion. This stimulation of LH secretion causes a temporary increase in testosterone lasting between 5 and 12 days. This is thought to account for the worsening of symptoms experienced by some men, known as ‘tumour flare’. This worsening of symptoms can be minimised by the administration of an anti-androgen for the first few weeks of treatment.

The four main LHRH agonists are:

  • goserelin (Zoladex®)
  • leuprorelin (Prostap®)
  • triptorelin (De-capeptyl®)
  • buserelin (Suprefact®)

Anti-androgens

Anti-androgens act by blocking the binding of testosterone to receptors on the surface of the prostate cancer cell. The main ones are:

  • cyproterone acetate (Cyprostat®)
  • flutamide (Drogenil®)

Bicalutamide (Casodex®) 150mg should not currently be used for patients with localised prostate cancer (defined as early disease).

This recommendation, from the Department of Health in 2003 (30), follows results from a study of bicalutamide in early prostate cancer which showed a trend for an increase in the number of deaths in patients receiving Casodex 150mg when compared with patients who received placebo.

The NICE guidelines (3) suggest that hormone therapy for early prostate cancer (in terms of medical castration) should be fully discussed with patients.

Surgery - orchidectomy

Surgery is less commonly used these days as medical hormone therapy has become available. It is as effective as LHRH agonists, and has the advantage that regular injections are not required, but , unlike LHRH agonists, the effect is irreversible.

Surgery involves a simple operation to remove both testicles (bi-lateral orchidectomy), or the parts of the testicles that produce testosterone (subcapsular orchidectomy). Surgery is done under a general, local or spinal anaesthetic. Testicular prostheses can be placed into the scrotum at the same time as the operation.


Content last reviewed: 01 May 2007
Page last modified: 31 January 2008

Get support

Look for other people in the same situation on our What Now? community - read their blogs or talk to them in our chat rooms.

Find out about other ways to get support on the main Macmillan website.

Patient information